KRAS and neoplasm: Currently, histological examination of tumor tissues is the gold standard for diagnosing the presence of mutations in KRAS. However, examining tissue samples has some disadvantages, as tumors and metastases are not always accessible for biopsy, collection of biopsies often requires invasive procedures, and intratumoral heterogeneity is not well understood.